American Century Companies Inc. Raises Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

American Century Companies Inc. increased its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 9.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,015,728 shares of the company's stock after purchasing an additional 88,882 shares during the quarter. American Century Companies Inc. owned 0.54% of BridgeBio Pharma worth $27,872,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Ironwood Investment Management LLC grew its holdings in shares of BridgeBio Pharma by 0.5% in the fourth quarter. Ironwood Investment Management LLC now owns 63,157 shares of the company's stock worth $1,733,000 after acquiring an additional 338 shares during the period. Steward Partners Investment Advisory LLC boosted its position in BridgeBio Pharma by 85.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after purchasing an additional 472 shares during the last quarter. Xponance Inc. boosted its position in BridgeBio Pharma by 9.1% in the fourth quarter. Xponance Inc. now owns 10,089 shares of the company's stock worth $277,000 after purchasing an additional 844 shares during the last quarter. Tocqueville Asset Management L.P. grew its stake in shares of BridgeBio Pharma by 7.2% during the 4th quarter. Tocqueville Asset Management L.P. now owns 18,975 shares of the company's stock valued at $521,000 after purchasing an additional 1,275 shares during the period. Finally, Advisors Asset Management Inc. grew its stake in shares of BridgeBio Pharma by 56.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company's stock valued at $117,000 after purchasing an additional 1,645 shares during the period. 99.85% of the stock is currently owned by institutional investors.

Remove Ads

Insider Buying and Selling at BridgeBio Pharma

In other news, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the company's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $34.90, for a total transaction of $106,989,998.40. Following the sale, the insider now directly owns 22,055,375 shares of the company's stock, valued at $769,732,587.50. This represents a 12.20 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brian C. Stephenson sold 68,000 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total value of $2,467,720.00. Following the transaction, the chief financial officer now owns 93,758 shares of the company's stock, valued at $3,402,477.82. This represents a 42.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 9,654,739 shares of company stock valued at $325,937,151 in the last 90 days. Insiders own 24.66% of the company's stock.

BridgeBio Pharma Stock Up 4.8 %

NASDAQ BBIO traded up $1.60 during trading hours on Wednesday, reaching $34.62. The company's stock had a trading volume of 1,964,997 shares, compared to its average volume of 2,204,986. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $39.47. The company has a market capitalization of $6.58 billion, a price-to-earnings ratio of -12.15 and a beta of 1.07. The firm's 50-day moving average price is $34.19 and its 200-day moving average price is $29.43.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The firm had revenue of $5.88 million for the quarter, compared to analysts' expectations of $4.04 million. Equities research analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Analysts Set New Price Targets

BBIO has been the topic of a number of research reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a report on Friday, February 21st. Scotiabank lifted their price target on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Friday, February 21st. JPMorgan Chase & Co. upped their price objective on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a research note on Monday, March 24th. Redburn Atlantic began coverage on BridgeBio Pharma in a research report on Monday. They set a "buy" rating and a $50.00 target price on the stock. Finally, Citigroup boosted their price target on BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a report on Friday, February 21st. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat, BridgeBio Pharma presently has a consensus rating of "Moderate Buy" and a consensus target price of $52.64.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.